This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS :To evaluate the change in directly measured LDL-c after the addition of ezetimibe to a stable background of HAART and statin therapy for 12 weeks compared with the change in LDL-c after 12 weeks of placebo.To evaluate the safety and tolerability of ezetimibe added to a stable background of HAART and statin therapy.Secondary Objectives:Evaluate the effect of ezetimibe on the following cardiovascular measures: Total cholesterol Non-high-density lipoprotein cholesterol (non-HDL-c) High-density lipoprotein cholesterol (HDL-c) Triglycerides C- reactive protein, high sensitivity (hsCRP) Apolipoprotein B (Apo B)?????
Showing the most recent 10 out of 1085 publications